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Abstract. A weekly administration of alternating irinotecan
or oxaliplatin associated to 5-Fluorouracil in advanced
colorectal cancer was planned in order to evaluate a new
schedule maintaining dose intensities of each drug as in double
combinations and tolerability of the triplet association. The
following weekly schedule was administered: irinotecan,
days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil
(5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat
infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dose-
finding and phase II study were planned. Thirteen patients
were enrolled in the dose-finding study and 23 in the phase II
study. The recommended doses of our study are: irinotecan
160 mg/m2; oxaliplatin 80 mg/m2; 5-FU 900 mg/m2. The dose-
limiting toxicity was diarrhea (35% of patients) but no cases
of febrile neutropenia were observed. In 30 patients
assessable for response two complete (6.7%) and 18 partial
(60%) responses were observed, for an overall response rate
of 66.7% (·0.05, CI±17). The triplet association using this
weekly alternating schedule is an active and well-tolerated
outpatient regimen. Surgical removal of residual disease was
considered in 5 patients and a radical resection was performed
in 5 patients (14%).
Introduction
Several phase I-II-III studies in metastatic colorectal cancer
(CRC) patients have been reported using different schedule of
triplet combinations of irinotecan (CTP-11), oxaliplatin (l-OHP)
and 5-fluorouracil (5-FU), showing higher response rate than
double associations of 5-FU with CPT-11 or l-OHP. Never-
theless the triplet combinations show G3-4 diarrhea and/or
febrile neutropenia as main toxic effects at the recommended
dose (RD) justifying a variable reduction of dose-intensity (DI).
We previously showed that 12-h (10 p.m.-10 a.m.) timed-
flat-infusion (TFI) of 5-FU in combination with docetaxel in
advanced breast cancer (1) and with CPT-11 in advanced
CRC (2) is associated to an increased tolerability and high
5-FU/DI. The 12-h (10 p.m.-10 a.m.) TFI/FU infusion traces
the 12-h circadian-timed infusion of 5-FU (10 p.m.-10 a.m.
with maximum delivery at 4 a.m.) and was chosen to exploit
the increased activity in the mononuclear cells of dehydro-
pyrimidine dihydrogenase (DPD), the enzyme involved in
5-FU intracellular catabolism, and the reduced proliferation
of normal target tissue, such as the bone marrow and the
oral/rectal mucosa, during the night hours (3-5).
LV modulation of infusional 5-FU, alone or in combi-
nation with new drugs such as CPT-11, increases gastro-
intestinal toxicity without increasing clinical benefit (6-8).
Thus, a weekly administration schedule of alternating
CPT-11 or l-OHP associated to TFI/5-FU, without leucovorin
(LV), was planned in order to maintain the DI of each drug
on the same level of the two drugs combinations and evaluate
tolerability. L-OHP was administered over 2-h as an intra-
venous infusion, from 3 p.m to 5 p.m., as the chronomodulated
infusion of l-OHP, peaking at 4 p.m., is less toxic than the
constant-rate infusion (9). Here, we present an analysis of
the safety and activity of this triplet schedule in metastatic
CRC, as first-line chemotherapy.
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Materials and methods
Patient selection. All the patients fulfilled the following cri-
teria: histologically confirmed diagnosis of CRC with clini-
cal evidence of metastatic disease; age between 18 and 75
years; WHO performance status ≤2; WBC count ≥4x103/mm3,
neutrophils ≥2x103/mm3, platelets ≥100x103/mm3, hemoglobin
≥10 g/dL, serum creatinine ≤1.2 mg/dL, serum bilirubin
≤1.5 mg/dL, AST and ALT ≤2.5 times normal value; life
expectancy more than 3 months. Exclusion criteria included:
prior chemotherapy for metastatic disease, peripheral neuro-
pathy, uncontrolled infection, diabetes, cardiac diseases.
The study was conducted in accordance with the Helsinki
declaration and the guidelines on good clinical practice. In
addition, the study protocol was approved by the appropriate
ethics review boards and each patient provided written
consent prior to study entry.
Treatment. The following weekly schedule was administered
on an outpatient basis: CPT-11, days 1 and 15; l-OHP over
2-h as an intravenous infusion (from 3:00 p.m. to 5:00 p.m.),
days 8 and 22; 5-FU over 12-h (from 10:00 p.m. to 10:00 a.m.)
timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4
weeks. In the dose-finding study eight escalation dose levels
were planned: CPT-11 180 mg/m2 and l-OHP 70 mg/m2
associated to 5-FU 700, 800 and 900 mg/m2/day in the first
3 dose-levels, respectively; then, l-OHP was increased at 80
mg/m2 and 5-FU dose-levels were increased from 900 to 1300
mg/m2/day according to a 100 mg/m2/d increase for each dose-
level in the other 5 steps. Placement of an implanted venous
access device was required. 5-FU was administered by means
of a portable pump (CADD Plus, SEVIT), programmed to
administer 5-FU at a given constant rate and to automatically
start the infusion at 10:00 p.m. for a period of 12 h. No
prophylactic treatment with granulocyte colony-stimulating
factor was used. To prevent nausea and vomiting, 5-HT3
antagonist i.v. were administered before chemotherapy and
atropine 0.25 mg was given prophylactically in order to
avoid cholinergic syndrome (Fig. 1).
Dose-finding study design. The dose-escalation strategy
combined the intra- and inter-patient approach (10). The
accelerated design included only one patient per cohort until
one patient experienced dose-limiting toxicity (DLT) or at
least two patient experienced grade (G) 2 toxicity (except
nausea or vomiting) during any course of treatment. After the
initial accelerated phase, the study resorted to standard
cohorts of 3 patients. If one or 2 patients experienced a DLT,
a second cohort was treated at the same dose-level. If no
more than two out of 6 patients experienced a DLT, the
next cohort of patients was treated at the subsequent dose-
level. The maximum tolerated dose (MTD) was defined as
the dose at which at least 50% of the newly treated patients
developed DLT.
Patients were evaluated for toxicity every week according
to National Cancer Institute Common Toxicity Criteria
version 2.0 (NCI-CTC). DLT included: G3 or G4 non-
hematological toxicity (except nausea or vomiting), G4
neutropenia, febrile neutropenia or any other hematological
G4 toxicity or any toxicity determining a treatment delay
longer than 2 weeks.
Phase II study design. The phase II patients were treated at
the recommended doses. The primary end points of the phase
II study were the best overall response rate and the safety.
The design parameters p0 (null hypothesis) and p1 (alter-
native hypothesis) selected were 0.4 and 0.6, respectively.
According to the Simon minimax two-stage design, a
final sample size of 28 patients with 14 responding patients
should have required to refuse the null hypothesis (·0.10,
ß0.20). The first stage of the study required 16 patients and if
at least 6 objective responses were observed, the second
stage required a total of 28 patients.
Tumor imaging was repeated every 3 treatment cycles (12
weeks). Tumor response was assessed and defined according
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Figure 1. Treatment schedule.
1635-1640.qxd  23/4/2010  10:01 Ì  ™ÂÏ›‰·1636
to Response Evaluation Criteria in Solid Tumors (RECIST)
criteria.
Patients were considered assessable for therapeutic
response if they had measurable lesions and if they received
more than 3 cycles.
Secondary end points were time to progression and
survival. The time to disease progression and survival were
assessed using the methods of Kaplan and Meier.
Results
Patients. Thirteen patients meeting eligibility criteria were
enrolled in the dose-finding study and 23 in the phase II study.
A summary of patients' baseline clinical features is shown in
Table I. The median age was 62 years (range 39-74); WHO
performance status was 0 in 30 patients (83%); 22 (61%) had
liver metastases (53% multiple) and 9 (25%) had received
previous adjuvant chemotherapy with 5-FU.
The median number of cycles administered in the dose-
finding and in the phase II study was 6 (range 0.5-9).
DLT and MTD. Table II describes the observed DLTs in
treated patients and cycles administered according to dose
levels.
Eight escalation dose-levels were planned, but MTD was
reached at the fifth dose level (5-FU DI 2000 mg/m2/week;
CPT-11 DI 90 mg/m2/week; l-OHP 40 mg/m2/week). The
first enrolled patient received the treatment according to
the intra-patient dose escalation from the first to the eighth
dose-level without showing G2 toxicity. The preliminary
analysis of the toxicity at fifth dose-level in 5 patients (the
sixth patient refused the dose-escalation), all previously
treated even at lower dose levels, did not detect any DLT.
In two cohorts of new patients enrolled at this dose-level
DLTs were observed in 3/6 new patients: one patient
experienced G3 diarrhea; one patient experienced G1 fever,
requiring a 2-week delay in chemotherapy and another one
G3 hypotension.
The fourth dose-level (5-FU DI 1800 mg/m2/week; CPT-
11 DI 90 mg/m2/week; l-OHP 40 mg/m2/week) represented
the RD: 7 patients were treated at this dose-level (3 pre-
treated at lower dose-levels and 4 newly treated) for a total
12 cycles. G3 diarrhea was observed in one patient, previously
treated at lower dose levels.
At the RD the G1-2 diarrhea was observed in 42% of patients
and 25% of cycles; G1-2 stomatitis in 28% of patients and 25%
of cycles; G1-2 nausea in 85% of patients and 58% of cycles;
G1-2 neurotoxicity in 28% of patients and 33% of cycles.
Phase II toxicity and dose intensity. The most common toxic
effects were diarrhea and stomatitis. Among 23 patients of
phase II study, eight (35%) had G3 diarrhea, eight (35%) had
G1-2 stomatitis (Table III), one (4%) had G4 neutropenia, three
(13%) had G3 neutropenia, six (26%) had G2 neutropenia and
one (4%) G3 peripheral neurotoxicity (Table IV). Although the
use of G-CSF was not planned, it was used in 10/126 (8%) of
cycles and 4/23 (17%) of patients: in 1 patient in secondary
prevention after experience of G4 neutropenia, in 3 patients
because persistent G2 leucopenia on the day of recycle did
not permit maintaining the planned weekly schedule. One
patient experienced G3 liver toxicity that required one week
delay until normalization of transaminases.
One patient (4%) experienced G4 neutropenia and no
cases of febrile neutropenia were observed (Table IV). No
toxic death occurred and no case of thrombosis correlated
to  venous access device has been registered.
In the first 18 patients enrolled in the phase II study
we observed 37.5% G3 diarrhea at a median received dose-
intensity (rDI) of CPT-11 70 mg/m2/week (78%). Thus, we
amended the protocol at 160 mg/m2 irinotecan dose for the
subsequent enrollment.
In the dose-finding study, 5-FU/rDI for each patient
was: the median 5-FU/rDI 1667 mg/m2/w (range 1143-2000)
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Table I. Clinical features of patients enrolled.
–––––––––––––––––––––––––––––––––––––––––––––––––
Total no. (%)
––––––––––––––––––––––––––––––––––––––––––––––––––––––
No. of patients 36
Sex
Male 22
Female 14
Age, years
Median 62
Range 39-74
>65 years 14 (39)
WHO performance status
0 30 (83)
1-2 6 (17)
Primary tumor
Colon 26 (72)
Rectum 10 (28)
No. of involved sites
1 26 (72)
≥2 10 (28)
Sites of metastases
Liver 22 (61)
Lung 8 (22)
Lynph nodes 7 (19)
Local 4 (11)
Other 6 (17)
Liver metastases
Single 3 (8)
Multiple 19 (53)
Previous adjuvant chemotherapy 9 (25)
FA/5-FU bolus 6 (17)
5-FU bolus + i.c. 2 (6)
Irinotecan/5FU 1 (3)
Previous radiotherapy 2 (6)
RT alone -
RT+CT (5-FU i.c.) 2 (6)
–––––––––––––––––––––––––––––––––––––––––––––––––
WHO, World Health Organization.
–––––––––––––––––––––––––––––––––––––––––––––––––
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and the average 1606 mg/m2/w (·0.05, CI±149). In the
phase II study 5-FU/rDI for each patient were: the median
5-FU/rDI 1476 mg/m2/w (range 900-1800) and the average
rDI 1407 mg/m2/w (·0.05, CI±94).
The received dose-intensity of 5-FU for patients
was 82% of planned DI, 87.5% of l-OHP and 82% of
CPT-11.
Antitumor activity. For the evaluation of activity, data from
the 13 patients enrolled in the dose-finding study were
considered together with data of the 23 patients enrolled in
the phase II study and treated at the recommended dose,
since the average dose intensity received by the two groups
were quite similar.
Of the 33 patients included in the intent-to-treat population,
30 patients were protocol-qualified. Reasons for failure to
satisfy protocol criteria included: not measurable disease in
2 patients enrolled in phase I study and one patient was lost
to follow-up (3 patients had not received at least 3 cycles of
treatment).
In the intent-to-treat analysis we observed 2/33 complete
responses and 21/33 partial responses with an overall response
rate of 69.6% ·0.05, CI±16). In 30 patients considered
assessable for response (as treated), two complete (6.7%) and
18 partial (60%) responses were observed, for an overall
response rate of 66.7% (·0.05, CI±17). We observed 3 stable
disease (10%) for a disease control rate of 76.7%. Response
data are summarized in Table V. Surgical removal of residual
disease was considered in 5 patients and a radical resection
(R0) was performed in 5 patients (all liver resections).
At 19 months of median follow-up, 23 deaths were
observed (64%). The median time to progression was 12
months (range 3+ - 61+). The median overall survival was 20
months (range 3+ - 61+).
Discussion
Our data propose the weekly 5-FU/TFI, without LV, in
association with alternating CPT-11/l-OHP characterized
by rDIs for each single drug equivalent to that proposed in
schedules of double associations (5-FU/CPT-11; 5-FU/l-OHP).
The recommended doses of our study are: CPT-11 at the
dose of 160 mg/m2, days 1 and 15; l-OHP over 2-h infusion
from 03:00 p.m to 05:00 p.m. at the dose of 80 mg/m2, days 8
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Table III. Non-haematological toxicity of phase II study.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
NCI-CTC grade (%) per cycles NCI-CTC grade (%) per patients
–––––––––––––––––––––––––––––––––––––– –––––––––––––––––––––––––––––––––––––
Adverse events 1 2 3 4 1 2 3                    4
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Nausea 30 (24) 12 (9.5) - - 10 (43) 6 (26) - -
Vomiting 13 (10) 11 (9) - - 7 (30) 6 (26) - -
Diarrhea 18 (14) 18 (14) 11 (9) - 3 (13) 8 (35) 8 (35) -
Stomatitis 16 (13) 1 (1) - - 6 (26) 2 (9) - -
Asthenia 33 (26) 16 (13) 1 (1) - 9 (39) 9 (39) 1 (4) -
Neurotoxicity 54 (43) 6 (5) 1 (1) - 14 (61) 2 (9) 1 (4) -
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
NCI-CTC, National Cancer Institute Common Toxicity Criteria.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Dose-limiting toxicities according to the dose-escalation scheme.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
CPT11 (mg/m2 d1,15)-
l-OHP (mg/m2 d8, 22)-
5-FU (mg/m2/d No. of patients No. of new patients No. of cycles with
d1-2, 8-9, 15-16, No. of patientsa with DLTb/total with DLT/new DLT/total cycles
Dose levels 22-23) (new patients) No. of cycles patients (%) patients (%) (%) DLTs
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
I 180-70-700 2 (2) 2 - - - -
II 180-70-800 3 (1) 3 - - - -
III 180-70-900 3 (0) 3 - - - -
IV 180-80-900 7 (4) 12 1/7 (14) - 1 (8) G3 Diarrhea
V 180-80-1000 11 (6) 30 3/11 (27) 3/6 (50) 3 (10) G3 Diarrhea
G1 Fever with
delay >2 weeks
G3 Hypotension
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aIntra- and inter-patient dose escalation; bdose-limiting toxicity.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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and 22; 5-FU over 12-h (from 10:00 p.m. to 10:00 a.m.)
timed flat infusion at a dose of 900 mg/m2, days 1-2, 8-9,
15-16 and 22-23, every 4 weeks. The 12-h infusion of 5-FU
is more easily administered in comparison with a chrono-
modulated infusion and demonstrates an high antitumor
activity and a tolerable toxic profile.
The relative dose-intensity of our schedule ranged between
82 and 87.5% of planned dose (CPT-11/DI 70; OHP/DI 35;
5-FU/DI 1476 mg/m2/week) and was characterized by G3
diarrhea in 35% of patients, G4 neutropenia in one patient
(4% of patients) and no febrile neutropenia.
The phase I-II studies of triplet associations in advanced
CRC, using different infusion of 5-FU and different DIs
of the three drugs, showed mainly severe diarrhea (range
2-72.2%) and/or febrile neutropenia (range 1-25%) at recom-
mended doses (11-32).
Most of these studies included LV. In our previous
doublet study we proposed a schedule excluding leucovorin
(1,2). Cals et al recommend a tolerable, weekly alternating
schedule characterized by higher 5-FU/DI (2.4 g/m2/w, 24-h
infusion) without LV, equivalent l-OHP (DI 32 mg/m2/w) but
lower (<50%) CPT-11/DI (40 mg/m2/w) than the present
study (17). The phase I-II study by Seium et al propose a
regimen with very high efficacy (the response rate was 78%)
but two febrile neutropenia episodes (one fatal) and diarrhea
(23% of patients; 3% of grade 4) were recorded (23).
The most active phase II studies were the following:
Ychou et al (16) reported a triplet combination according to
the De Gramont infusion of 5-FU with G3-4 diarrhea in
29.4% and febrile neutropenia in 3% of patients, respectively
and the response rate (RR) was 70.6% (31); Calvo et al
reported G3-4 diarrhea in 34.5% of patients and the overall
RR was 69.2% (13). The most tolerable phase II study, as first-
line advanced chemotherapy, was proposed by Ferrari et al,
but the antitumor activity of triplet combination with bolus
5-FU was lower (RR 50%) (26).
The relative dose-intensity of schedule recommended
by Falcone et al ranged between 82 and 87% of planned dose
(CPT-11/DI 82.5; OHP/DI 42.5; 5-FU/DI 1600 mg/m2/week)
and was characterized by G3-4 diarrhea, G4 neutropenia and
febrile neutropenia in 20, 17 and 5% of patients, respectively.
The response rate confirmed by external panel was 60% and
in particular 15% of patients underwent to radical surgery
in the FOLFOXIRI arm (34).
This triplet regimen is an active (RR 66.7%) and usually
well-tolerated outpatient regimen. Surgical removal of residual
disease was considered in 5 patients and a radical resection
(R0) was performed in 5 patients (14%).
Present data show that the triplet combination in ACC
may be administered according to a weekly alternating
administration without leucovorin. This schedule is equally
effective as the schedules showing higher activity and shows
better tolerability concerning neutropenia.
It also shows almost equivalent activity as doublet com-
binations adding Bevacizumab or Cetuximab. Ongoing studies
are exploring the possibility of adding antitargets to the
triplet schedules in advanced colorectal cancer.
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